Objective-Interventions that promote liver-directed cholesterol flux can suppress atherosclerosis, as demonstrated for scavenger receptor-BI overexpression in hypercholesterolemic mice. In analogy, we speculate that increasing lipoprotein flux to the liver via the asialoglycoprotein receptor (ASGPr) may be of therapeutic value in hypercholesterolemia. Methods and Results-A bifunctional glycolipid (LCO-Tyr-GalNAc 3 ) with a high-nanomolar affinity for the ASGPr (inhibition constant 2.1Ϯ0.2 nmol/L) was synthesized that showed rapid association with lipoproteins on incubation with serum. Prior incubation of LCO-Tyr-GalNAc 3 with radiolabeled low-density lipoprotein or high-density lipoprotein (0.5 g/g of protein) resulted in a dramatic induction of the liver uptake of these lipoproteins when injected intravenously into mice (70Ϯ3% and 78Ϯ1%, respectively, of the injected dose at 10 minutes of low-density lipoprotein and high-density lipoprotein), as mediated by the ASGPr on hepatocytes. Intravenously injected LCO-Tyr-GalNAc 3 quantitatively incorporated into serum lipoproteins and evoked a strong and persistent (Ն48 hour) cholesterol-lowering effect in normolipidemic mice (37Ϯ2% at 6 hours) and hyperlipidemic apoE Ϫ/Ϫ mice (32Ϯ2% at 6 hours). The glycolipid was also effective on subcutaneous administration.
C linical data indicate a positive correlation between lowdensity lipoprotein (LDL) cholesterol levels and the occurrence of arteriosclerosis, 1,2 whereas a strong inverse correlation has been demonstrated between high-density lipoprotein (HDL) cholesterol levels and cardiovascular disease. 3, 4 Current therapies for hypercholesterolemia are mainly focused on enhancing the hepatic clearance and catabolism of LDL and very low-density lipoprotein (VLDL) by the induction of LDL receptors (LDLrs) in the liver through inhibition of cholesterol synthesis by 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors ("statins") or stimulation of biliary cholesterol excretion with bile-acid sequestrants ("resins"), 5 leaving HDL levels relatively unaffected. However, recent findings indicate that the antiatherogenic capacity of HDL is not determined by its steady-state level in the serum, per se, but rather by its kinetics and functionality, which governs the cholesterol flux from peripheral cells to the liver ("reverse cholesterol transport"), 6 -10 as reviewed by Von Eckardstein and Assmann. 11 Permanent overexpression of the hepatic HDL receptor (scavenger receptor BI [SR-BI]) in heterozygous LDLr-deficient mice on a high-fat/ high-cholesterol diet, resulted in a strong reduction in plasma HDL cholesterol (90%) and atherosclerotic lesion area. 9 Even temporary stimulation of reverse cholesterol transport by transient hepatic overexpression of SR-BI in these mice, which resulted in a transient lowering of plasma HDL cholesterol (55%) and apolipoprotein AI (40%) levels, led to a significant decrease in lesion formation. 10 These studies clearly illustrate that stimulation of the hepatic uptake of LDL and HDL will be an effective entry to antiatherosclerotic therapy and incited us to explore the feasibility to induce effective clearance of these lipoproteins via the asialoglycoprotein receptor. 12 This high-capacity receptor is uniquely expressed on the surface of hepatocytes to mediate the hepatic uptake and subsequent lysosomal processing of galactose (Gal) and N-acetylgalactosamine (GalNAc)-terminated substrates from the serum, 13 at which the affinity for GalNAc is Ϸ50-fold higher than for Gal. 14 Previous proof-of-concept studies already showed that bifunctional glycolipids [TG(4Å)C and TG(20Å)C], consisting of a cholesteryl moiety for anchorage to lipoproteins and a triantennary Gal-terminated glycoside with moderate affinity for the ASGPr, were able to associate with lipoproteins and induce their liver uptake in rodents. However, TG(4Å)C induced the hepatic uptake of LDL by Kupffer cells instead of hepatocytes, 15 exerted a cholesterol-lowering effect only at high doses (Ն35 mg/kg), and had to be administered by slow infusion because of its hemolytic properties. 16 TG(20Å)C was somewhat more effective, but the hepatocyte-targeted delivery of lipoproteins was still suboptimal because of rapid redistribution of the glycolipid from lipoproteins in serum 17 and inability to induce the hepatic uptake of triglyceride-rich lipoproteins, such as VLDL. 18 The aim of the present study was to improve the hepatocyte-directed lipoprotein targeting efficiency of the glycolipids by enhancing their affinity for both lipoproteins and the ASGPr. For this purpose, we synthesized a novel triantennary glycolipid (LCO-Tyr-GalNAc 3 ) with a highly lipophilic lithocholic oleate (LCO) structure, 19 and a high-nanomolar affinity for the ASGPr. These modifications indeed resulted in a highly improved induction of lipoprotein uptake (LDL, VLDL, and HDL) by hepatocytes and a concomitantly enhanced hypocholesterolemic potency. Strong and persistent cholesterol-lowering effects were observed in normolipidemic and hyperlipidemic mice and even after subcutaneous injection. We conclude from these data that LCO-Tyr-GalNAc 3 is very effective in promoting cholesterol transport to hepatocytes and, thus, may be a promising alternative for hyperlipidemic individuals who do not respond sufficiently to current cholesterol-lowering therapies, such as familial hypercholesterolemic patients. 20, 21 
Methods
Please see an expanded version of the Methods section online, available at http://atvb.ahajournals.org.
Animals
Male mice (C57Bl/6 background), fed ad libitum with regular chow, were used. The study was approved by the ethics committee of the Leiden University. Figure I , available online at http://atvb.ahajournals.org) were synthesized as described. 19, 22 
Glycolipids

Isolation and Characterization of Lipoproteins
Human lipoproteins were isolated from healthy volunteers, 23 and protein was determined according to Lowry et al 24
Radiolabeling of Lipoproteins and LCO-Tyr-GalNAc 3
LDL and AcLDL were radioiodinated as described. 25 LCO-Tyr-GalNAc 3 was radioiodinated using a Iodogen (10 g)-coated reaction tube. HDL and AcLDL were radiolabeled with [ 3 H]cholesteryl oleate (CO). 25
Association of LCO-Tyr-GalNAc 3 With Lipoproteins
Sera were incubated with LCO-[ 125 I]Tyr-GalNAc 3 and electrophoresed on agarose gels. Lipids were visualized by Sudan black and 125 I activity using a Packard Instant Imager.
Kinetic Studies in Mice
Mice were anesthetized, 19 and kinetic studies with radiolabeled lipoproteins were performed as described. 26 The contribution of hepatocytes to the hepatic uptake of lipoproteins was determined by the isolation of hepatocytes at 10 minutes after injection. 15 Conscious mice were injected via the tail vein with LCO-[ 125 I]Tyr-GalNAc 3 and placed in metabolic cages. After 48 hours, the mice were killed, and 125 I activity was determined in their organs, feces, and urine.
Macrophage Association Studies In Vivo
Mice were injected intraperitoneally with Brewer's thioglycollate medium. After 5 days, mice were injected with radiolabeled lipoproteins with or without glycolipid. After 1 hour, mice were euthanized by cervical dislocation, and macrophages were isolated by peritoneal lavage with 10 mL of ice-cold PBS and washed 3 times with PBS. Cellular protein was determined according to Lowry et al, 24 and radioactivity was counted.
Cholesterol-Lowering Effect of Glycolipids
PBS or glycolipids were injected intravenously into the tail vein or subcutaneously into the neck region of conscious mice. Blood samples were taken from the tail vein, and the sera were analyzed for total cholesterol. The distribution of lipids over lipoproteins was determined by fast protein liquid chromatography (Superose 6).
Statistical Analysis
Statistical significance was determined by using the 2-tailed Student t test, repeated measures ANOVA, and Dunnett t test. Values are expressed as means, and errors represent the variation between data points (in case of nϭ2) or SD (nՆ3).
Results
Incorporation of LCO-Tyr-GalNAc 3 Into Serum Lipoproteins
Incubation of LCO-Tyr-GalNAc 3 with human serum resulted in a concentration-dependent reduction of the electrophoretic mobility of the lipoproteins (LDL, VLDL, and HDL), whereas the mobility of albumin was not affected relatively to the front marker bromophenol blue ( Figure 1A ). Similar results were obtained using LCO-Gal 3 (data not shown). Analysis of the distribution of LCO-[ 125 I]Tyr-GalNAc 3 over the serum components showed association of the glycolipid mainly with LDL and HDL and virtually no binding to albumin ( Figure 1B) . Whereas LCO-[ 125 I]Tyr-GalNAc 3 preferentially bound to LDL in human serum ( Figure 1B) , the glycolipid predominantly associated with HDL in wild-type mouse serum ( Figure 1C ) and to (␤-)VLDL and LDL in apoE Ϫ/Ϫ serum ( Figure 1D ).
Effect of LCO-Tyr-GalNAc 3 on the Hepatic and Splenic Uptake of Lipoproteins in Mice
On intravenous injection into wild-type mice, the hepatic uptake of 125 I-LDL and [ 3 H]CO-labeled HDL were negligible (Ͻ1% of the dose at 10 minutes after injection). Prior incubation of LCO-Tyr-GalNAc 3 with LDL or HDL caused a dose-dependent acceleration of the serum clearance of both lipoproteins and enhanced their liver uptake reaching 70Ϯ3% and 78Ϯ1% of the dose (10 minutes after injection), respectively, at 0.5 g of glycolipid per microgram of particle protein (Figure 2A and 2C). At this glycolipid loading, the ASGPr-selective inhibitor asialoorosomucoid (ASOR) 27 inhibited the glycolipid-induced hepatic clearance of LDL and HDL by 63% ( Figure 2B ) and 94% ( Figure 2C ), respectively, indicating that the induced hepatic clearance of both lipoproteins is mainly mediated by the ASGPr on hepatocytes. Liver cell distribution studies confirmed the prominent role of hepatocytes in the uptake of LDL (52.3Ϯ1.5%) and HDL (95.6Ϯ0.7%; nϭ2). LCO-Gal 3 enhanced the hepatic clearance of both lipoproteins to a similar extent as LCO-Tyr-GalNAc 3 , but the enhanced liver uptake of LDL could not be inhibited by ASOR (data not shown). Also, whereas LCO-Gal 3 enhanced the association of LDL with the spleen by 33.5-fold, LCO-Tyr-GalNAc 3 did not affect the splenic uptake (and extrahepatic distribution in general) of both lipoproteins (data not shown).
Effect of LCO-Tyr-GalNAc 3 on the Association of Lipoproteins With Macrophages in Mice
Preincubation of 125 I-LDL with the highest dose of glycolipid used in the kinetic studies (0.5 g per microgram of protein) did not enhance the association of 125 I-LDL with thioglycolate-ellicited macrophages in the peritoneal cavity in vivo (ϩ7%, not significant; Figure IIA , available online at http://atvb.ahajournals.org). Likewise, the glycolipid did not significantly affect the association of [ 3 H]CO-HDL with macrophages (ϩ31%, not significant; Figure IIB) . In fact, the total accumulation of 125 I-LDL and [ 3 H]CO-HDL remained much lower than that of 125 I-AcLDL and [ 3 H]CO-AcLDL, respectively. Other than the observation that LCO-Tyr-GalNAc 3 did not increase the extrahepatic distribution of LDL and HDL, the glycolipid apparently does not increase the affinity of both lipoproteins with nonresident macrophages either.
Kinetic Studies on Glycolipids in Mice
We have shown recently that LCO-[ 125 I]Tyr-GalNAc 3 almost completely associates with HDL after intravenous administration to wild-type mice and that the clearance from serum (half time Ϸ30 minutes) could mainly be attributed to uptake by the liver (44Ϯ3% at 60 minutes after injection). 22 Intravenous injection of LCO-[ 125 I]Tyr-GalNAc 3 (1.0 mg/kg) into conscious mice now revealed that, in addition to uptake by the liver, glycolipid-derived radioactivity is also excreted in feces and urine, as shown at 48 hours after injection ( Figure  IIIA , available online at http://atvb.ahajournals.org). Interestingly, a similar pattern of hepatic uptake and excretion from the body was found after subcutaneous administration of the glycolipid (5.0 mg/kg; Figure IIIB) . Assuming that the radioactivity recovered in the intestinal tract and feces result from biliary secretion of (metabolized) glycolipid by the liver, it can be calculated that 56.9Ϯ2.3% (Ϸ570 g) and 16 .3Ϯ0.3% (Ϸ815 g) of the doses have reached the liver at 48 hours after intravenous and subcutaneous injection, respectively.
Cholesterol-Lowering Effect of Glycolipids in Mice
On intravenous injection of LCO-Gal 3 into conscious wildtype mice, a significant and dose-dependent hypocholesterolemic effect was detected [repeated measures ANOVA; F(2,5)ϭ14.3; PϽ0.01], at which the effects of both doses differed significantly from the control group (Dunnett t test: 1.0 mg/kg: PϽ0.05; 3.3 mg/kg: PϽ0.01; Figure 3A ). At 3.3 mg/kg, the effect peaked at 3 hours (28.4%; PϽ0.01) and was still significant (PϽ0.05) up to 12 hours after injection. LCO-Tyr-GalNAc 3 also evoked a significant dose-dependent hypocholesterolemic effect on intravenous injection [F(2,6)ϭ72.4; PϽ0.001], with both effects significantly different from the control group (1.0 mg/kg: PϽ0.001; 3.3 mg/kg: PϽ0.001; Figure 3B ). However, as compared with LCO-Gal 3 , the effects were even more pronounced (36.5% at 6 hours after injection of 3. Figure 3C ). The effects had a slower onset and did not reach a maximum before 24 hours after injection (20.7% at 48 hours after administration of 16.7 mg/kg; PϽ0.01). The effect of intravenous injection of LCO-Tyr-GalNAc 3 (10 mg/kg) was also examined in apoE Ϫ/Ϫ mice that have Ϸ10-fold higher total cholesterol (TC) levels than wild-type mice on a regular diet. Also, in these severely hyperlipidemic mice, LCO-Tyr-GalNAc 3 appeared highly effective, because it caused a 32Ϯ2% (PϽ0.001) decrease in serum TC at 6 hours after injection, and a statistically significant effect (24Ϯ5%; PϽ0.05) was still observed at 24 hours after injection ( Figure  3D ). Importantly, 3 consecutive injections of LCO-Tyr-GalNAc 3 into apoE Ϫ/Ϫ mice at 72-hour time intervals resulted in consistent effects on TC reduction (27% to 32% after 6 hours; Figure 3E ).
Effect of LCO-Tyr-GalNAc 3 on Mouse Serum Lipoproteins In Vivo
To investigate the effects of the glycolipids on the serum levels of the individual lipoprotein classes, serum was taken from wild-type mice, before and 3 hours after injection of LCO-Tyr-GalNAc 3 (10 mg/kg), and was subjected to fast protein liquid chromatography ( Figure 4A and 4B) . The eluted fractions containing VLDL/chylomicrons, intermediate-density lipoprotein/LDL, HDL, and the total bed volume were pooled, and the total cholesterol ( Figure 4A ) and glycerol ( Figure 4B ) contents were determined. The decrease in the total cholesterol content of the fractions (42.6Ϯ1.6%; meanϮSEM; PϽ0.001) could be attributed to a decrease in cholesterol in VLDL (61.3Ϯ5.6%; PϽ0.05), LDL (29.2Ϯ1.4%; PϽ0.01), and HDL (43.8Ϯ1.5%; PϽ0.001). The total glycerol content of the fractions, a measure of triglyceride content, tended to be decreased (10.8Ϯ7.2%; not significant), but a significant reduction was observed for the glycerol content of VLDL (PϽ0.05). Likewise, injection of LCO-Tyr-GalNAc 3 (10 mg/kg) into apoE Ϫ/Ϫ mice resulted in a 25.5% reduction of TC (PϽ0.05), which was caused by a decreased cholesterol content of VLDL (24.5%; PϽ0.05), LDL (26.3%; PϽ0.05), and HDL (39.9%; PϽ0.05). Similar effects were observed on glycerol reduction, which only was significant for VLDL (PϽ0.05; Figure 4C and 4D).
Toxicity of Glycolipids in Mice
The absence of toxicity of LCO-Tyr-GalNAc 3 was verified in wild-type mice (after single injection) and in apoE Ϫ/Ϫ mice (after 3 consecutive injections at 72-hour time intervals) at the highest dose applied in vivo (Table I , available online at http://atvb.ahajournals.org). In accordance with the results shown above, a bolus injection of LCO-Tyr-GalNAc 3 (10 mg/kg) in wild-type mice led to a significant reduction of plasma TC after 3 hours (37.8%; PϽ0.0001), which persisted for Ͼ24 hours (16.8%; PϽ0.05) as compared with control animals, leaving total plasma glycerol and protein levels unchanged (PϾ0.05). The serum parameters for systemic (lactate dehydrogenase) and liver toxicity (ASAT, ALAT, and ␥GT) remained unaffected at 3 and 24 hours after injection. No changes were observed in liver, heart, kidney, and spleen weight at both time points. Similarly, repeated injections of LCO-Tyr-GalNAc 3 in apoE Ϫ/Ϫ mice did not affect body and organ weights, and no effects were observed on the serum levels of lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and ␥-glutamyl transferase, as determined at 48 hours after the third injection. In addition, no signs of hemolysis were observed after incubation of heparinized blood with LCO-Tyr-GalNAc 3 at concentrations equivalent to doses of 100 mg/kg (data not shown).
Discussion
It is becoming increasingly clear that net cholesterol fluxes, rather than steady-state serum cholesterol levels, are instrumental to the occurrence of atherosclerosis. 11 In particular, it has been shown in mice that the flux of LDL cholesterol and HDL cholesterol to the liver dictates the cholesterol homeostasis in the periphery. As shown by Kozarsky et al 10 and Arai et al, 9 overexpression of the HDL receptor SR-BI, be it transient or permanent, strongly decreases serum HDL levels (cholesterol and apolipoprotein AI) and atherosclerosis. Likewise, strategies aimed at stimulating the hepatic LDLrmediated uptake of LDL and VLDL in humans also reduce serum cholesterol and atherosclerosis. 1, 2, 5 As such, interventions that promote the transport of LDL, VLDL, and HDL to hepatocytes, the only cell type able to irreversibly excrete cholesterol from the body, 28 may be effective in suppressing the atherogenic process.
Our newly developed glycolipid LCO-Tyr-GalNAc 3 is superior to the parent compounds, because it combines stable incorporation into lipidic particles 19 and a high affinity and selectivity for the ASGPr. 29 The highly hydrophobic character of the lithocholic oleate moiety indeed resulted in an avid and quantitative association of the glycolipids with lipoproteins in vitro, withstanding dissociation of the glycolipids in the blood to endogenous lipoproteins. Therefore, both LCO-Gal 3 and LCO-Tyr-GalNAc 3 evoked a dose-dependent monophasic serum decay of both LDL and HDL, with a concomitant highly induced uptake of both lipoproteins by the liver (reaching 70% to 80%). In contrast, at similar concentrations, TG(20Å)C induced the liver uptake of LDL and HDL to only 20% to 25% and 35%, respectively. 17 The potential therapeutic value of the glycolipids could not only be appreciated from their enhanced ability to promote the hepatic uptake of lipoproteins but also from their ability to induce ASGPr-mediated hepatocyte-specific uptake. It appeared that LCO-Gal 3 induced the uptake of LDL by Kupffer cells and spleen, instead of hepatocytes. Probably, the conformational properties of the individual galactose clusters, which are critical for proper recognition by the ASGPr, 19 may be overruled by high-local surface concentrations of the surface of LDL. In contrast, LCO-Tyr-GalNAc 3 enhanced the uptake of LDL mainly by hepatocytes. This indicates that the disturbing effects of sugar density on receptor specificity can be overcome by strongly enhancing the affinity of the triantennary glycoside for the ASGPr, as we have also demonstrated for 30 nm-sized liposomes. 29 Importantly, LCO-Tyr-GalNAc 3 also did not increase the association of LDL and HDL with peritoneal macrophages in vivo, suggesting that the glycolipid will not promote foam cell formation in the arterial wall by enhancing lipid accumulation into subendothelial macrophages. Indeed, we have evaluated the uptake of glycolipid-laden radiolabeled 125 I-LDL and [ 3 H]CO-HDL by the aorta in mice, and we were not able to detect the presence of radioactivity above the background level (data not shown).
Because these glycolipids are aimed to evoke a cholesterol-lowering effect on administration to hyperlipidemic patients, they should accumulate into endogenous lipoproteins before being cleared by the liver. From LCO-[ 125 I]Tyr-GalNAc 3 turnover studies, it can indeed be concluded that rapid binding of glycolipids to lipoproteins does occur, leading to a progressive uptake of glycolipid by the liver. 22 This resulted in remarkably persistent dose-dependent decreased serum cholesterol concentrations, at which LCO-Tyr-GalNAc 3 showed an Ϸ3-fold higher hypocholesterolemic potency than LCO-Gal 3 . Because it is clear that an enhanced ASGPr-mediated uptake of lipoproteins results in an enhanced secretion of bile acids, 18 this pathway will ultimately lead to an increased fecal secretion of cholesterol.
LCO-Tyr-GalNAc 3 not only caused a reduction of LDL and HDL cholesterol, but also of VLDL cholesterol, which was not observed for either TC(20Å)C 18 or LCO-Gal 3 (data not shown). These observations are in agreement with our recent findings that GalNac-terminated glycolipids can effi-ciently induce the uptake of particles with a size Յ70 nm by hepatocytes, whereas Gal-terminated glycolipids are ineffective. 29 Clearly, replacement of Gal by GalNAc within the glycolipid not only dramatically enhances the affinity of glycolipids for the ASGPr (inhibition constant, 2 nM versus 190 nM), but also largely improves the specificity of HDL, LDL, and (␤-)VLDL for the ASGPr on hepatocytes versus the GPr on Kupffer cells. Therefore, despite the significantly different (LDLϩVLDL)/HDL molar ratios in wild-type mice (Ϸ0.2) and apoE Ϫ/Ϫ mice (Ϸ30), the hypocholesterolemic effects of LCO-Tyr-GalNAc 3 in both the normolipidemic and hyperlipidemic mice were similar. This is an important observation with respect to application in humans (Ϸ3.0), because LCO-[ 125 I]Tyr-GalNAc 3 predominantly associates with LDL in human serum. In addition, repeated administrations of LCO-Tyr-GalNAc 3 resulted in consistent TCreducing effects in apoE Ϫ/Ϫ mice, which indicates its suitability for long-term therapeutic usage in hypercholesterolemia.
In conclusion, we have shown that LCO-Tyr-GalNAc 3 is a very effective inducer of lipoprotein uptake by the hepatic ASGPr, even after relatively noninvasive subcutaneous administration, without any sign of adverse effects. The HDL lowering capacity is similar to that evoked by transient hepatic overexpression of SR-BI, which was found to retard atherogenesis in LDLr-deficient mice. 10 Therefore, if such an effect on atherogenesis can also be observed in humans, LCO-Tyr-GalNAc 3 -induced hepatic uptake of lipoproteins that include HDL may be an effective entry to hyperlipidemia-induced atherosclerotic therapy, which can be of benefit for those patients who do not respond to conventional 3-hydroxy-3-methylglutaryl-coenzyme A reductaseinhibiting cholesterol-lowering therapies.
